To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
News | Press release | Health ＆ life sciences | Toxicology | Virus
Researchers from CEA and the Institut Curie have improved the mechanism of action of a molecule capable of neutralizing the harmful effect of a large number of pathogens, including the Ebola virus, enterohemorrhagic Escherichia coli and cholera toxin. These results, published in Nature Chemical Biology on 17 February 2020, pave the way for the development of a broad-spectrum drug.
Resources are lacking in terms of treatment for many toxic viruses and bacteria, which are the cause of recent health crises (Ebola virus, Shiga toxin-producing E. coli, cholera, etc.).
For several years, CEA and the Institut Curie have been working to develop a revolutionary approach to treatment: rather than targeting the pathogens directly, scientists from both organizations are seeking to block the cellular mechanism that they depend on to produce their harmful effects. A few years ago, they developed and synthesized compounds called Retro-2 (CEA-Institut Curie patents) capable of blocking the harmful action of many pathogens.
They demonstrated the in-vitro efficacy of these molecules against 3 toxins, 12 viruses, 3 intracellular bacteria and 2 parasites (Gupta et al., 2017). Efficacy has also been proven in vivo in mice against ricin, enterohemorrhagic E. coli, vaccinia virus (smallpox model), enterovirus 71 (a virus causing severe brain damage in children), cytomegalovirus (causing infections in immunosuppressed individuals) and two species of the leishmaniasis parasite. However, further pre-clinical in-vivo tests were required prior to pharmaceutical formulation to identify the precise cellular mechanism that explains the protective action of Retro-2, which had been poorly understood until now.
In a new study published in Nature Chemical Biology on 17 February 2020, researchers from CEA and the Institut Curie, in collaboration with the Carnegie Mellon Institute in the United States, shed light on this mechanism. They discovered that molecules of the Retro-2 family bind to the cellular protein Sec16A and block its effect. Sec16A controls the circulation in the cell of syntaxin-5, a protein that in turn controls the progression of viruses and toxins.
Having identified the intracellular target of Retro-2, researchers can now look at developing a drug candidate with a broad spectrum of applications.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.